Allergy

The 150 mg once-daily pellet formulation gives patients aged ≥ 12 years a capsule alternative for HAE prophylaxis.

Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.

Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.

In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.

DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.

Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

Two monoclonal antibodies isolated from malaria-exposed donors blocked patient IgE from binding key alpha-gal allergens and suppressed basophil activation.

Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.

What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.

The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.

In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.